- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Monoclonal antibody no better than placebo for early Parkinson's disease: NEJM
USA: Cinpanemab, a monoclonal antibody, is no better than placebo as a disease-modifying treatment for Parkinson's disease, according to a recent study published in the New England of Medicine.
The study stated that "the effects of cinpanemab on clinical measures of disease progression and changes in dopamine transporter single-photon-emission computed tomography (DaT-SPECT) imaging did not differ from those of placebo over a 52-week period in patients with early Parkinson's disease."
Aggregated α-synuclein plays an important part in the pathogenesis of Parkinson's disease. Cinpanemab is a human-derived monoclonal antibody that binds to α-synuclein. It is being evaluated as a disease-modifying treatment for Parkinson's disease.
For this purpose, Anthony E. Lang and colleagues conducted a 52-week, multicenter, double-blind, phase 2 trial that included 357 participants with early Parkinson's disease. They were randomly assigned in the ratio of 2:1:2:2 to receive intravenous infusions of placebo (control; n=100) or cinpanemab at a dose of 250 mg (n=55), 1250 mg (n=102), or 3500 (n=100) mg every 4 weeks. This was followed by an active-treatment dose-blinded extension period for up to 112 weeks.
Changes from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (range, 0 to 236, with higher scores indicating worse performance) at weeks 52 and 72 were the primary endpoints. Secondary endpoints were MDS-UPDRS subscale scores and striatal binding as assessed on DaT-SPECT.
Key findings of the study include:
- The trial was stopped after the week 72 interim analysis owing to lack of efficacy.
- The change to week 52 in the MDS-UPDRS score was 10.8 points in the control group, 10.5 points in the 250-mg group, 11.3 points in the 1250-mg group, and 10.9 points in the 3500-mg group (adjusted mean difference vs. control, −0.3 points; and 0.1 points respectively.
- The adjusted mean difference at 72 weeks between participants who received cinpanemab through 72 weeks and the pooled group of those who started cinpanemab at 52 weeks was −0.9 points for the 250-mg dose, 0.6 points for the 1250-mg dose, and −0.8 points for the 3500-mg dose.
- Results for secondary endpoints were similar to those for the primary endpoints.
- DaT-SPECT imaging at week 52 showed no differences between the control group and any cinpanemab group.
- The most common adverse events with cinpanemab were headaches, nasopharyngitis, and falls.
"The effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo in In participants with early Parkinson's disease, over a 52-week period," the researchers conclude.
Reference:
The study titled, "Trial of Cinpanemab in Early Parkinson's Disease," was published in the New England Journal of Medicine.
DOI: 10.1056/NEJMoa2203395
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751